Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (2)

Trial Status

Withdrawn1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07713732Phase 1Not Yet Recruiting

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

NCT05375825Phase 1WithdrawnPrimary

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Showing all 2 trials

Research Network

Activity Timeline